Anthony's questions to WAVE Life Sciences Ltd (WVE) leadership • Q1 2025
Question
An analyst from Raymond James asked which specific biomarkers the company plans to report from the ENLIGHT trial for its WVE-007 obesity candidate.
Answer
President and CEO Dr. Paul Bolno stated that the disclosed biomarkers for the upcoming readout will include changes in body weight and levels of Activin E (the protein product of the INHBE gene). He explained that tracking Activin E will serve as a key measure of target engagement and will also help inform the durability of the drug's effect over time. He mentioned that other exploratory biomarkers are also being assessed in the study.